These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22327136)

  • 1. Correlation between paraproteinaemia and viral reactivation after allo-SCT.
    Metafuni E; Giammarco S; Bellesi S; Chiusolo P; Laurenti L; Sorà F; Cattani P; Santangelo R; Manzara S; Leone G; Sica S
    Bone Marrow Transplant; 2012 Sep; 47(9):1262; author reply 1263. PubMed ID: 22327136
    [No Abstract]   [Full Text] [Related]  

  • 2. Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation.
    Medd P; Littlewood S; Danby R; Malladi R; Clifford R; Wareham D; Jeffery K; Ferry B; Roberts D; Peniket A; Littlewood T
    Bone Marrow Transplant; 2011 Jul; 46(7):993-9. PubMed ID: 20956951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath.
    Bainton RD; Byrne JL; Davy BJ; Russell NH
    Blood; 2002 Nov; 100(10):3843-4. PubMed ID: 12411329
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytomegalovirus retinitis.
    Rothova A; de Weerdt O
    Ophthalmology; 2009 Apr; 116(4):817-8; author reply 818-9. PubMed ID: 19344836
    [No Abstract]   [Full Text] [Related]  

  • 5. Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: a search for the guilty.
    Chakrabarti S
    Blood; 2003 Mar; 101(5):2071. PubMed ID: 12584145
    [No Abstract]   [Full Text] [Related]  

  • 6. Similar lymphocyte recovery and CMV reactivation profiles between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation.
    Hill QA; Hill A; Collyns TA; Pearce RM; Cook G
    Bone Marrow Transplant; 2008 Apr; 41(8):749-51. PubMed ID: 18195685
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients.
    Satwani P; Baldinger L; Freedman J; Jacobson JS; Guerra J; van de Ven C; Morris E; Garvin J; George D; Bradley MB; Bhatia M; Tallamy B; Schwartz J; Jin Z; Cairo MS
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1587-95. PubMed ID: 19896083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
    Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
    Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.
    Avivi I; Chakrabarti S; Kottaridis P; Kyriaku C; Dogan A; Milligan DW; Linch D; Goldstone AH; Mackinnon S
    Bone Marrow Transplant; 2004 Jul; 34(2):137-42. PubMed ID: 15235576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus infections following chemotherapies of the newer generation.
    Junghanss C
    Haematologica; 2005 Dec; 90(12):1591. PubMed ID: 16330430
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
    Ingram W; Devereux S; Das-Gupta EP; Russell NH; Haynes AP; Byrne JL; Shaw BE; McMillan A; Gonzalez J; Ho A; Mufti GJ; Pagliuca A
    Br J Haematol; 2008 Apr; 141(2):235-43. PubMed ID: 18318762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation.
    Vu T; Carrum G; Hutton G; Heslop HE; Brenner MK; Kamble R
    Bone Marrow Transplant; 2007 Jun; 39(11):705-9. PubMed ID: 17401392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late onset cytomegalovirus encephalitis after reduced-intensity conditioning allogeneic SCT: an emerging neurological complication?
    Candoni A; Simeone E; Buttignol S; Volpetti S; Lazzarotto T; Pipan C; Fanin R
    Bone Marrow Transplant; 2011 Mar; 46(3):455-6. PubMed ID: 20498649
    [No Abstract]   [Full Text] [Related]  

  • 15. Polyoma viruria following T-cell-depleted allogeneic transplants using Campath-1H: incidence and outcome in relation to graft manipulation, donor type and conditioning.
    Chakrabarti S; Osman H; Collingham K; Milligan DW
    Bone Marrow Transplant; 2003 Mar; 31(5):379-86. PubMed ID: 12634729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
    Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
    J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
    Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
    Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
    Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus.
    Liu YC; Lu PL; Hsiao HH; Chang CS; Liu TC; Yang WC; Lin SF
    Ann Hematol; 2012 Apr; 91(4):587-95. PubMed ID: 21997849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab.
    Bokhari S; Das-Gupta E; Russell N; Byrne J
    Bone Marrow Transplant; 2008 Aug; 42(4):281-2. PubMed ID: 18490912
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.